Authors
Latest:
Why agility is the key to navigating the fast-changing healthcare landscapeOutlining the key digital trends accelerated by the transformed healthcare landscape in 2021—and their impact on pharma commercialization strategies going forward
Latest:
More changes ahead: Biopharma market trends for rest of 2021The evolving topics to keep a close watch on in the coming months
Latest:
'Next-Best-Action' for Data AnalyticsHow to make commercial AI actionable in the last mile, helping to better realize data science investment and improve customer engagement
Latest:
The Challenges of Safety Risk Detection: The Automation SolutionIf there’s anything we learned from the pandemic, it’s the critical need to analyze patient outcome data in real time to stay informed on the safety and efficacy of treatments in the real world
Latest:
A Pharma Pricing and Agreements Primer in Today's Complex LandscapeIn order to provide both profitability and medication access, a balancing act is required.
Latest:
What Goes into Planning LogiPharma Europe?A dive into the intricacies of how to ensure a long-running event stays fresh and relevant to the needs of the pharmaceutical industry.
Latest:
New Blueprint for HCP RelationshipsThree keys to achieving digital excellence in the next normal, where a hybrid commercial model will be the standard for physician engagement
Latest:
Critical power: The lifeline for pharmaceutical manufacturingOutlining the business-vital areas pharma organizations should consider today in energy risk management, including the value of resiliency
Latest:
The Cultural Divide Between IT & OT Puts Critical Operations at Risk.Sponsored by Dragos, the Ponemon Institute’s report on the State of Industrial Cybersecurity finds that cultural and technical differences between traditional IT best practices and what is possible in OT increases an organization’s risk for costly cyber incidents – and the average cost to detect, investigate, and remediate an event.
Latest:
The Value in Committing to Conscientious Corporate StewardshipWhy is it important for organizations to set long-term goals when planning for a sustainable future?
Latest:
Key learnings to support biosimilar commercialization in the USTaking cues from launches so far in oncology and rheumatology, three important considerations for biosimilar marketability are outlined
Latest:
How Serious Are You About Patient Centricity?Companies need to alter their thinking to better prioritize patients. Here are three simple yet impactful engagement elements that could help.
Latest:
Getting to answers about Biogen’s AduhelmExploring RCT, RWE and alternative study designs as a path forward
Latest:
Ensuring Compliance and Quality of Pharmaceutical TransportFor pharma companies, an investment in a digital risk management tool is worth considering if they want to meet the European Union's regulatory requirements for pharmaceutical transport and wholesalers
Latest:
The Case for Domestic Sourcing to Establish Reliable Pharmaceutical Supply Chains in the United StatesReliance on foreign imports means that disruptions in the supply chain can profoundly impact the ability of individuals in the United States to get access to the medications they need.
Latest:
Aligning Medical Information and PVAs companies seek interoperability across their organizations, a joint approach to medical information and local pharmacovigilance may deliver future benefits
Latest:
A New Approach to the Commercialization Challenges Facing the Oncology IndustryBy 2024 oncology therapeutic sales will hit $250 billion worldwide, and there will be more than 22 million cancer survivors. But commercializing how these critical therapies come to market to help patients hasn’t changed much in the past 20 years. The industry must do more, write Anne Marie Robertson and Ellen Cappellino
Latest:
Making Sustainable Omnichannel ChangeA look into ways to approach change management using three factors.
Latest:
The Consolidated Appropriations Act and PBM TransparencyNew federal law introduces significant changes in the design of pharmacy benefit plans with aims to level the playing field between PBMs and their employee healthcare benefit plan clients.
Latest:
Breaking the Chains of Opioid Addiction: The Promise of Long-Acting InjectablesAs providers and healthcare professionals recognize the potential of long-acting injectables to fight the opioid epidemic, many are actively transitioning from oral options to injectables.
Latest:
How Digital Twins Drive Sustainability in Clinical Supply PlanningDigital twins allow the industry to integrate sustainable practices and supply chain efficiency solutions while ensuring patient safety.
Latest:
Unlocking Pharma 4.0 Through Edge ComputingCreating a meaningful digital transformation requires pharmaceutical manufacturing companies to incorporate the right technologies, processes, and systems to reach their fullest potential.
Latest:
Building the Cold Chain of the FutureWith today's greater combination of technology and know-how, we must design new ways to handle sensitive pharmaceuticals—and do it together
Latest:
Caught Beneath the Surface: The Hidden Potential of Patient DataFilling the gaps in the patient journey within an increasingly complex data environment.
Latest:
Cell and gene therapy success: Overcoming patient and provider apprehensionThe benefits of establishing an in-depth go-to-market commercialization strategy for a new CGT in the beginning of clinical trials
